ISO 10993-1:2025 Biological Evaluation Plan Builder
Help medical-device teams assemble a controlled Biological Evaluation Plan working package that links the final finished device, biological hazards, endpoint questions, evidence routes, study plans, risk records, and qualified decisions without automating scientific or regulatory judgment.
Package at a glance
11 ZIP entries
The current customer archive passed exact-inventory, checksum, and deterministic-rebuild QA.
17 workbook sheets
A fail-closed working system with sample content kept separate.
3-page Quick Start
A concise route through the files, controls, and escalation points.
24 official sources
Source status, limitations, retrieval dates, and recheck triggers.
A traceable working record—not a shortcut to a conclusion
Traceable device scope, biological-hazard, evidence-route, test-planning, and qualified-decision controls
Controlled BEP Scope Record
A controlled BEP scope record tied to one final finished device configuration, intended use, contact profile, population, markets, and decision request.
Traceable Hazard Map
A biological-hazard and endpoint-question map that starts with device mechanisms and exposure instead of copying a generic test list.
Endpoint Evidence-Route Plan
A traceable evidence-route plan showing existing evidence, applicability limits, gaps, proposed studies, and the qualified decision owner for each question.
Qualified Decision Handoff
A final-finished-device, test-article, sample-preparation, protocol, chemistry, toxicology, and animal-welfare planning record with explicit stop conditions.
What the current customer edition contains
The verified v3.0 archive contains 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. Final document, workbook, visual, and archive-integrity QA are complete.
Quick Start PDF
Define the exact candidate, follow the eight-step safe sequence, and recognize stop conditions before entering conclusions.
Complete when: The team knows the device boundary, owners, source date, workflow, review sequence, and non-conclusions.
Implementation Guide PDF
Apply the device, hazard, endpoint, evidence, study, risk, lifecycle, and jurisdiction controls with current source-status boundaries.
Complete when: The team can explain every planned route, limitation, action, reserved decision, and reopening trigger.
Editable Working Templates DOCX
Draft the BEP charter, source record, device/exposure profile, hazard map, endpoint schedule, evidence bridge, study controls, regulatory bridge, and decision memo.
Complete when: Every response is device specific, traceable, reviewed, and free of fictional or unresolved instruction text.
Operational Workbook XLSX
Control project facts, official sources, contact, materials/process, hazards/endpoints, evidence, articles, chemistry/TRA, studies, assessment, risk/regulatory links, red flags, actions and decisions.
Complete when: No invalid or incomplete control remains, every open/blocked action is resolved, and every terminal decision is fully evidenced and reviewed.
Source Status and Release Notes PDF
Verify current ISO publication, FDA recognition, final/draft guidance, dynamic template, EU MDR, and CDSCO status.
Complete when: The source register matches the exact controlled standards and official sources used for the candidate event.
Customer README, responsible-use terms, and CSV source register
Orient recipients, preserve identity and boundaries, and support controlled internal use.
Complete when: Title, IDs, version, files, source date, support route, restrictions, and use boundaries agree.
Inspect the actual working system
These are direct renders of the current v3.0 workbook prepared as public product views, not marketing mock-ups. Select any image to inspect it at full size.
How the resource is intended to be used
The complete Quick Start and implementation guide are included in the current v3.0 customer edition. This public walkthrough lets a buyer inspect the operating logic and stop conditions before requesting an exact offer.
Controlled BEP charter
Freeze the exact device, final finished state, use, population, markets, decision request, exclusions, owners, and source date.
Stop if: The candidate, decision, market, or owner is unclear.
Contact and exposure profile
Map every direct and indirect contact path, tissue or fluid, duration, frequency, cumulative use, population, and configuration.
Stop if: A path, time, population, or repeated-use assumption is unknown.
Material and process map
Describe component formulations, processing, cleaning, residues, surfaces, sterilization, packaging, ageing, degradation, and supplied state.
Stop if: A trade name or certificate replaces final-device facts.
Hazard and endpoint-question map
Identify biological hazards and device-specific questions; route endpoint applicability to qualified review.
Stop if: A generic endpoint or legacy test list is being reused.
Evidence ledger and applicability bridge
Register evidence, appraise quality, bridge each article to the candidate, preserve contrary data, and open every gap.
Stop if: Identity, locator, article, method, result, limitation, or bridge is missing.
Qualified evidence-generation plan
Plan chemistry, toxicology handoff, articles, preparation, protocols, laboratories, and animal-welfare controls where justified.
Stop if: A test or waiver is automated, or article, ethics, or review controls are missing.
Risk and regulatory bridge
Link planned conclusions and uncertainties to risk, clinical, PMS, CAPA, change, jurisdiction, and lifecycle records.
Stop if: Risk, market, contrary-evidence, or reopening links are absent.
Controlled BEP review candidate
Recheck sources, reconcile IDs, remove fictional content, resolve actions, and route the exact candidate for independent review.
Stop if: A stop flag, stale source, invalid state, missing reviewer, or open action remains.
Current public authorities behind the working controls
Sources were checked 2026-08-02; next planned portfolio recheck is 2026-11-02. Live status must still be verified at each material decision or submission event.
ISO · ISO 10993-1:2025 catalog record
Edition 6 was published in November 2025. ISO describes a reorganized, ISO 14971-aligned biological-evaluation framework with updated exposure, material-characterization, and biological-hazard guidance. Use a lawfully obtained controlled copy.
FDA · FDA recognition record 2-313 - ISO 10993-1:2025
Partial recognition entered 2026-05-25. FDA identifies excluded content, an implementation caution, and transition from the prior recognized edition through 2029-07-01.
FDA · FDA transition record 2-258 - ISO 10993-1:2018
Prior partially recognized edition. FDA records transition to recognition 2-313 through 2029-07-01; the excluded Table A.1 and other record-specific limitations remain relevant to use of this record.
FDA · Use of International Standard ISO 10993-1 - final guidance, September 2023
Final FDA guidance. Apply with current recognition records, device-specific guidance, and the actual final finished device; it predates publication of ISO 10993-1:2025.
FDA · Biocompatibility Evaluation Endpoints by Device Category
Current FDA resource used as a planning orientation. It is not an automatic test list and does not replace device-specific, risk-based evaluation or review-division input.
ISO · ISO 14971:2019 catalog record
Edition 3 remains published and was confirmed in 2025. The standard establishes a lifecycle risk-management process but does not set acceptable risk levels.
What the resource deliberately does not promise
Clear boundaries protect the buyer and make the working records more useful to qualified reviewers.
Clear boundary 1
No automated endpoint applicability, test selection, waiver, no-new-testing, representative or worst-case, toxicological-acceptability, or biological-safety decision.
Clear boundary 2
No completed BER, risk-management file, clinical evaluation, laboratory report, TRA, submission, eSTAR, GSPR checklist, Device Master File, or regulator response.
Clear boundary 3
No FDA clearance, EU conformity, CE marking, CDSCO licence, notified-body acceptance, submission readiness, or regulator-acceptance prediction.
Clear boundary 4
No reproduction of ISO standards or replacement for lawfully obtained standards, current legal text, guidance, recognition records, device-specific requirements, ethics approval, or qualified professional review.
Questions to settle before requesting an offer
Is the current v3.0 edition available?
Yes. The current v3.0 customer edition is released and available by request. Online checkout, payment, customer download, and automatic delivery are not currently enabled. Use Request Exact Offer to receive the controlled offer before deciding whether to pay.
What is included in the current v3.0 edition?
The verified archive contains 11 ZIP entries: 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. It includes a 3-page Quick Start, 18-page implementation guide, 13-page editable templates, and 17-sheet workbook. Final document, workbook, visual, and archive-integrity QA are complete.
Does the resource provide a completed regulatory or biological conclusion?
No. It provides a traceable working system. Device-specific conclusions, testing decisions, toxicological judgments, and submission decisions require qualified review.
Can I inspect the product before requesting an offer?
Yes. This page shows the complete workflow and real v3.0 product views, while the downloadable 5-page public preview explains the scope, operating logic, included files, and important limits.
How to Build a Medical-Device Biological Evaluation Plan
Start with the informational BEP guide for scope, device facts, evidence routes, endpoint questions and the plan-to-report connection.
Review the workflow now. Request the exact current offer.
No order, payment, customer download, or delivery is created through this page. The controlled offer identifies the exact version, licence, price, update option, policies, and delivery method for your review before any payment decision.